MyBody-X angle on Abnehmspritze Check

MyBody-X's angle on weight loss injection checks (e.g., GLP-1 agonists like semaglutide) is evidence-based and consumer-protective. Direct genetic testing to predict response to these drugs is not currently part of the standard portfolio. Existing DNA analyses (e.g., metabolism genes like APOE, COMT, or CLOCK) provide only weak, associative hints about weight trends or satiety behavior – not clinically validated prediction for injection therapy success. The efficacy of weight loss injections depends on multiple factors: hormonal status, liver and kidney function, concomitant medication, and lifestyle. A single SNP from a consumer test cannot capture this complex pharmacodynamics. MyBody-X therefore emphasizes: such checks are intended as lifestyle inspiration, not as a medical decision basis. Anyone considering a weight loss injection should seek medical advice and possibly order clinical pharmacogenetics (e.g., GLP-1 receptor genes). The evidence for pure DNA checks in this area is weak ('unclear'). Safety note: weight loss injections have side effects (nausea, pancreatitis); a genetic risk assessment without clinical validation is insufficient.